Comparing two add-on treatments for type 2 diabetes
Part of Hormones & metabolism clinical trials.
This trial compares adding a new pill (cofrogliptin) to increasing your current metformin dose, for people whose blood sugar is still too high despite taking an SGLT2 inhibitor and a low dose of metformin. The goal is to see which option works better and is safer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age between 18 and 74 years old
- Diagnosed with type 2 diabetes
- Currently taking a standard SGLT2 inhibitor pill for at least 8 weeks
- Taking 500–1000 mg of metformin daily for at least 8 weeks, with no recent dose changes
- Your HbA1c (average blood sugar over 2-3 months) is between 7.5% and 9.5%
- Your fasting blood sugar is below 15 mmol/L
- Weigh less than 40 on the BMI scale
- No ketones in your urine (a sign of serious diabetes complication)
- Kidney function (eGFR) is 60 or higher
- Able to monitor your blood sugar at home and stick with your current diet and exercise plan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two oral diabetes pills, cofrogliptin and linagliptin, when added to your current insulin treatment. The goal is to see if these pills help improve blood sugar control without causing extra side effects.
This study compares two oral diabetes medicines, cofrogliptin and acarbose, to see which works better and has fewer side effects in people who are new to diabetes medication. If you qualify, you would take one of these pills daily, and the study will help you manage your blood sugar.
This trial tests how combining a ketone supplement with certain diabetes medicines affects blood sugar and ketone levels. It may help adults with type 2 diabetes who are not on insulin or certain other drugs.
This trial tests a combination of three common diabetes medications (metformin, an SGLT2 inhibitor, and a TZD) to see how well they work together and if they are safe. It may help people with type 2 diabetes who need better blood sugar control.
This study tests a new medicine (HM11260C) to see if it helps people with type 2 diabetes who are already taking metformin and dapagliflozin but still have high blood sugar. If you qualify, it could give you a new option to better control your diabetes.
This trial tests how stopping a type 2 diabetes medication called an SGLT2 inhibitor affects the liver's production of sugar and ketones. It may help understand better ways to manage diabetes.
Hear when a new Type 2 diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.